B A C K G R O U N D
Prompt and effective malaria treatment can prevent uncomplicated malaria from developing into more severe illness. The World Health Organization (WHO) promotes this as a major component of national malaria control programmes (WHO 2000) . However, identifying effective drugs or combinations of drugs is hampered by antimalarial drug resistance. This is a problem in many African countries where the disease is common and the burden is high ( WHO 1999) .
The Plasmodium falciparum parasite is responsible for most of the malaria burden in Africa (WHO 1999) . For decades, chloroquine was the first-line treatment for falciparum malaria, but parasite resistance has lead to this being replaced (White 1998) . Several East, Central, and Southern African countries (such as Malawi, Kenya, Botswana, and South Africa) have changed their national policy for first-line treatment to sulfadoxine-pyrimethamine. Other countries, such as Uganda, are using combinations of sulfadoxinepyrimethamine and chloroquine (Verhoeff 1997; D'Alessandro 2001) .
One problem with sulfadoxine-pyrimethamine is that parasites can develop resistance to it relatively quickly. Sulfadoxine and pyrimethamine act on two different enzymes in the folate biosynthetic pathway, which are essential for the survival of the malaria parasites. Specific parts of the parasite's DNA code for these enzymes, and they can mutate in such a way that the enzyme still functions but is protected from the effect of sulfadoxine and pyrimethamine. Sulfadoxine-pyrimethamine has a long half-life, which encourages the selection of the mutant (resistant) parasites, and resistance can develop rapidly (Triglia 1999) . Resistance to sulfadoxine-pyrimethamine is already widespread in South-East Asia and South America, and is becoming more common in Africa (WHO 1988; Warsame 2002) .
A more recent and potential alternative to sulfadoxinepyrimethamine is the combination of chlorproguanil and dapsone. Like sulfadoxine-pyrimethamine, chlorproguanil-dapsone is an antifolate drug combination (White 1998) . This combination acts on two sequential steps of the Plasmodium (malaria parasite) folate biosynthetic pathway. First, dapsone prevents the formation of folic acid, and then chlorproguanil interferes with the conversion of folic acid to folinic acid. This theoretically means the effects of the two drugs are synergistic (Thompson 1972) .
Chlorproguanil and dapsone have both been used for malaria prophylaxis. Chlorproguanil, as Lapudrine, has been used singly whereas dapsone has been used in combination with pyrimethamine (Maloprim). In The Gambia, chlorproguanil has been used for over five years with no reported resistance developing, but there is concern over cross-resistance between chlorproguanil and pyrimethamine (Greenwood 1989; Allen 1990) . The development of resistance to chlorproguanil-dapsone should be slow because both drugs are rapidly eliminated from the body (mean half life of dapsone is 20 to 30 hours, chlorproguanil 12 to 20 hours) and therefore exert low selection pressure for resistance (Curtis 2002) . However similarities in the mechanism of development of resistance between sulfadoxine-pyrimethamine and chlorproguanil-dapsone may limit the effectiveness of chlorproguanildapsone (Le Bras 2003) .
Dapsone has adverse effects (Thompson 1972) , including methaemoglobinaemia, haemolysis, and anaemia (red blood cell disorders). They are thought to occur after long-term continuous use and are more frequent with doses of 100 mg or more per day (Wolf 2002) . More serious adverse effects include agranulocytosis and hypersensitivity. Other adverse effects with dapsone include dermatitis, hepatitis, anorexia, nausea, vomiting, headache, nervousness, blurred vision, haematuria, drug fever, and psychoses ( Ozawa 2002).
Chlorproguanil-dapsone was developed mainly for use in Africa as a replacement for the rapidly failing sulfadoxine-pyrimethamine. Chlorproguanil-dapsone (LapDap) has been approved for general use in the United Kingdom by the UK Medicines and Healthcare products Regulatory Agency, and has been launched in Zambia, Kenya, Cameroon, Ghana, and Nigeria (GlaxoSmithKline 2003; ZANA 2003) . The current standard is a fixed-ratio tablet of 2.0:2.5 mg/kg (80:100 mg adult formulation and 15:18.75 mg paediatric formulation) of chlorproguanil and dapsone respectively, taken once daily for three days. However, lower doses of chlorproguanil have previously been tested.
We have summarized the evidence for the role of the chlorproguanil-dapsone combination for treating uncomplicated falciparum malaria. We have used the WHO's definition in order to differentiate between the uncomplicated and severe (complicated) forms of malaria (WHO 2001) . Our primary outcomes are positive blood slide for P. falciparum on day 14 and day 28. In areas of intense transmission, positive blood smears after day 14 may be the result of new infections or a recrudescence of the old infection. Polymerase chain reaction (PCR) can be used to differentiate between new and old infections.
O B J E C T I V E S
To compare chlorproguanil-dapsone with other antimalarial drugs for treating uncomplicated falciparum malaria.
M E T H O D S Criteria for considering studies for this review

Types of studies
Randomized and quasi-randomized controlled trials.
Types of participants
Adults and children with microscopically confirmed uncomplicated falciparum malaria (WHO 2001) .
Types of interventions Intervention
Chlorproguanil-dapsone.
Control
Current drug regimens for treating uncomplicated falciparum malaria.
Types of outcome measures
Primary
• Presence of falciparum malaria parasites on day 14.
• Presence of falciparum malaria parasites on day 28, adjusted for new infection using PCR analysis.
Secondary
• Parasite clearance time.
• Time to fever clearance.
• Treatment failure (early treatment failure, late treatment failure (late clinical failure, and late parasitological failure) ( WHO 2002; see Table 1 for definitions). 
Expression Definition
Early treatment failure Development of danger signs or severe malaria on day 1, day 2, or day 3, in the presence of parasitaemia; or parasitaemia on day 2 higher than day 0 count irrespective of axillary temperature; or parasitaemia on day 3 with axillary temperature 37.5°C or higher; or parasitaemia on day 3 of 25% of count on day 0 • Use of antipyretic (paracetamol, other).
• Mean haemoglobin.
Adverse events
• Serious adverse events: adverse events that lead to death, require hospitalization or prolongation of existing hospitalization, are life threatening, or result in persistent or significant disability or incapacity.
• Adverse events that require the discontinuation of treatment.
• Number of people experiencing adverse events.
Search methods for identification of studies
We attempted to identify all relevant trials regardless of language or publication status (published, unpublished, in press , and in progress).
Databases
We searched the following databases using the search terms and strategy described in 
Researchers and pharmaceutical companies
We contacted scientists working in the field of malaria, and GlaxoSmithKline, the pharmaceutical company that manufactures chlorproguanil-dapsone (LapDap), for any unpublished trials.
Reference lists
We also checked the reference lists of all trials identified by the above methods.
Data collection and analysis
Selection of studies
Hasifa Bukirwa (HB) scanned the results of the literature search, retrieved potentially relevant trials, and checked the eligibility with Julia Critchley (JC) using a standard form. We resolved ambiguity by discussion or by contacting the authors for clarification and additional information.
Data extraction and management
HB and JC independently extracted trial characteristics and data.
Where the number randomized and the numbers analysed were inconsistent, we calculated the percentage loss-to-follow-up and reported this in the 'Characteristics of included studies'. We had intended to primarily consider trials with intention-to-treat analysis, but only two trials had any outcomes analysed in this way ( Alloueche 2004; Sulo 2002) . For dichotomous outcomes, we recorded the number of participants experiencing the event in each group of the trial. For continuous outcomes, we extracted the arithmetic means and standard deviations for each group.
Assessment of risk of bias in included studies
HB and JC assessed the methodological quality of the included trials using generation of allocation sequence, allocation concealment, blinding of the participants and clinicians, and loss to follow up. We have classed generation of allocation sequence and allocation concealment as adequate, inadequate, or unclear according to Jüni 2001. We considered loss to follow up as adequate (acceptable) if it was 10% or lower. We classed blinding as open (all parties are aware of treatment), single blind (participant or care provider/assessor is aware of the treatment given), or double blind (trial uses a placebo or a double dummy technique such that neither the participant or care provider/assessor know which treatment is given).
Data synthesis
We analysed data using Review Manager 5. We calculated the risk ratio (RR) for dichotomous data and mean difference (MD) for continuous data, and presented both with 95% confidence intervals (CI). We assessed heterogeneity among included trials by visually inspecting forest plots and carrying out a chi-squared test for heterogeneity (statistical significance at 10% level). We have stratified analyses according to dosing regimen of chlorproguanildapsone. We used the fixed-effect model to pool data because we did not detect heterogeneity. Although we planned to carry out subgroup analyses based on the following subgroups, we did not perform this because few trials were identified. This may be possible in future updates of this review.
• Participant age (≤ 5 years versus > 5 years).
• Setting of the trial: (1) high versus low endemicity (high = hyperendemicity or holoendemicity and low = hypoendemicity or mesoendemicity); and (2) level of resistance to the comparator drug.
R E S U L T S Description of studies
See: Characteristics of included studies; Characteristics of excluded studies; Characteristics of ongoing studies. Six trials (n = 3352) met our inclusion criteria ('Characteristics of included studies'). We excluded two trials ('Characteristics of excluded studies') and one trial is ongoing ('Characteristics of ongoing studies'). Four trials included children aged between 1 and 6 years, one included children aged 3 to 13 years, and one included schoolgirls and pregnant women (Keuter 1990) . One trial compared chlorproguanil-dapsone with sulfadoxinepyrimethamine in participants who had already failed on sulfadoxine-pyrimethamine (Mutabingwa 2001).
Intervention
All trials compared chlorproguanil-dapsone with sulfadoxinepyrimethamine. One trial also included a chloroquine arm ( Keuter 1990) .
Dose and regimen
Dose and regimen varied across trials. Two trials used 1.2 mg/kg chlorproguanil and 2.4 mg/kg dapsone: Keuter 1990 administered it as a single dose; and Amukoye 1997 administered it as a single dose in one group and as daily dose for three days in another group. Watkins 1988 used a single dose of 1.2 mg/kg chlorproguanil and 8 mg/kg dapsone in Kilifi, and 1.2 mg/kg chlorproguanil and 2.4 mg dapsone in Entasopia. The 1.2 mg/kg chlorproguanil dose used in Amukoye 1997, Keuter 1990, and Watkins 1988 is lower than the dose in the currently standard fixed-ratio tablet and as used in the other three trials. Three trials used 2 mg/kg chlorproguanil and 2.5 mg/kg dapsone for three days ( 
Resistance
Resistance to the comparator drug is mentioned in four trials: resistance to sulfadoxine-pyrimethamine was low in Kenya (Kilifi) (Sulo-Kenya); present to some extent in Malawi (Blantyre) ( Sulo-Malawi); and high in the Tanzania trial (Mutabingwa 2001). Resistance to chloroquine was high in Kenya (Keuter 1990) , but the level of resistance to sulfadoxine-pyrimethamine is not clear in this trial. Watkins 1988 and Amukoye 1997 do not describe the background resistance to sulfadoxine-pyrimethamine, but it may be inferred to be low because the trials were carried out at an earlier time period in the same area as Sulo-Kenya.
Outcomes
All but one trial reported the presence of parasites at various time points (Sulo 2002) ; Alloueche 2004 provided data on parasitaemia on request. No trials reported on parasite clearance time and time to fever clearance. We obtained data on fever at various time points from Alloueche 2004 on request. Treatment failure was reported by all the trials. We were unable to present data on the use of antipyretics because the only trials that mentioned them − Amukoye 1997 and Sulo 2002 − either gave them uniformly or did not give sufficient detail to allow further analyses. All trials mentioned adverse events, but only some described the procedure to identify them.
Risk of bias in included studies
The methodological quality of the included trials is summarized in Table 3 . Generation of allocation sequence was adequate in three trials, and inadequate in the trials that allocated treatment to women in blocks of three according to the order that they came in (Keuter 1990) For blinding, the three trials with adequate allocation concealment also concealed the allocation to the participants and to the assessors. Two trials had no blinding, and one did not describe methods for blinding (Watkins 1988 
Effects of interventions
One-dose chlorproguanil-dapsone regimen (with 1.2 mg chlorproguanil)
Versus chloroquine
One trial with a 28-day follow up assessed this regimen (Keuter 1990) .
Parasitaemia
Parasitaemia tended to be lower with chlorproguanil-dapsone at days 7, 14, 21, and 28 (Analysis 1.1). However, this was not statistically significant for the two primary review outcomes of day 14 (RR 0.55, 95% CI 0.17 to 1.80; n = 153) and day 28 (RR 0.77, 95% CI 0.34 to 1.74; n = 110).
Treatment failure by day 28
Chlorproguanil-dapsone had fewer treatment failures than chloroquine (RR 0.41, 95% CI 0.26 to 0.63; n = 165, Analysis 1.2).
Adverse events
This trial did not describe any procedure to identify adverse events, and none were reported.
Versus sulfadoxine-pyrimethamine
Three trials compared a one-dose regimen with sulfadoxinepyrimethamine (Watkins 1988; Keuter 1990; Amukoye 1997) .
Parasitaemia
More participants treated with chlorproguanil-dapsone than sulfadoxine-pyrimethamine had parasitaemia by day 14 and day 28 (Analysis 2.1); the difference was statistically significant at day 28 (RR 3.11, 95% CI 2.28 to 4.24; n = 527).
Treatment failure by day 28
The risk of treatment failure was much higher for the chlorproguanil-dapsone group compared with the sulfadoxinepyrimethamine group (RR 2.77, 95% CI 1.86 to 4.10; n = 547, Analysis 2.2).
Adverse events
Only Amukoye 1997 reported this, with no events with chlorproguanil-dapsone compared with three serious adverse events ("parasitaemic and admitted to hospital") in the sulfadoxinepyrimethamine group. This was not statistically significant ( Analysis 2.3).
Three-dose chlorproguanil-dapsone regimen (with 1.2 mg chlorproguanil) Versus sulfadoxine pyrimethamine
One trial assessed this regimen (Amukoye 1997).
Parasitaemia
At day 28, statistically significantly more participants treated with chlorproguanil-dapsone had parasitaemia compared with those treated with sulfadoxine-pyrimethamine (RR 2.07, 95% CI 1.41 to 3.03; n = 294, Analysis 3.1). No results were reported for parasitaemia at day 14, and no statistically significant difference was detected at day 7 (Analysis 3.1).
Treatment failure by day 28
Chlorproguanil-dapsone was associated with statistically significantly more treatment failures than sulfadoxine-pyrimethamine (RR 2.27, 95% CI 1.27 to 4.05; n = 294, Analysis 3.2).
Mean haemoglobin
No statistically significant difference in mean haemoglobin was demonstrated between participants when assessed on days 0, 7, 14, 21, and 28 (Analysis 3.3).
Adverse events
One adverse event was recorded with chlorproguanil-dapsone, and three serious adverse events ("parasitaemic and admitted to hospital") with sulfadoxine-pyrimethamine; the difference was not statistically significant (Analysis 3.4).
Three-dose chlorproguanil-dapsone regimen (with 2.0 mg chlorproguanil)
Versus sulfadoxine-pyrimethamine (previous sulfadoxinepyrimethamine failures)
One trial examined people who had failed on sulfadoxinepyrimethamine and needed re-treatment (Mutabingwa 2001).
Parasitaemia
No results were available for day 14 or day 28, but by day 7 chlorproguanil-dapsone was statistically significantly better at clearing parasites than sulfadoxine-pyrimethamine (RR 0.11, 95% CI 0.04 to 0.34; n = 90, Analysis 4.1).
Treatment failure by day 7
There were statistically significantly fewer treatment failures with chlorproguanil-dapsone by day 7 (RR 0.11, 95% CI 0.04 to 0.33; n = 92, Analysis 4.2).
Treatment failure by day 28
This was not reported.
Adverse events
Only one adverse event, which occurred in the sulfadoxinepyrimethamine group, was reported; and the difference in the number of adverse events was not statistically significantly different (Analysis 4.3). 
Parasitaemia
Alloueche 2004 reported that parasitaemia was statistically significantly lower with chlorproguanil-dapsone at day 7 (RR 0.31, 95% CI 0.15 to 0.63; n = 1850) and day 14 (RR 0.56, 95% CI 0.37 to 0.85; n = 1850); see Analysis 5.1.
Presence of fever
Alloueche 2004 reported no statistically significant difference in the presence of fever (defined as temperature ≥ 37.5 ºC) at day 7 (RR 0.77, 95% CI 0.42 to 1.42; n = 1850) or day 14 (RR 1.58, 95% CI 0.79 to 3.17; n = 1850); see Analysis 5.2.
Treatment failure by day 7
Sulo 2002 reported that chlorproguanil-dapsone was associated with statistically significantly fewer treatment failures than sulfadoxine-pyrimethamine (RR 0.30, 0.19 to 0.49; n = 827, Analysis 5.3).
Treatment failure by day 14
Alloueche 2004 reported that chlorproguanil-dapsone was associated with statistically significantly fewer treatment failures than sulfadoxine-pyrimethamine (RR 0.36, 95% CI 0.24 to 0.53; n = 1709, Analysis 5.4). Sulo 2002 did not report this outcome.
Treatment failure by day 28
Neither trial reported this outcome.
Mean haemoglobin
Alloueche 2004 assessed mean haemoglobin on days 0, 3, 7, and 14 (Analysis 5.5). Day 14 haemoglobin was only measured for a small number of participants whose day 7 results caused concern. Mean haemoglobin tended to be lower for participants on chlorproguanil-dapsone than sulfadoxine-pyrimethamine at each time point, but this was statistically significant only at day 7 (MD -0.40 g/dL, 95% CI -0.62 to -0.18; n = 1701).
Adverse events
Adverse events recorded included vomiting, diarrhoea, anorexia, abdominal pain, pneumonia, severe malaria, skin rash, red blood cell disorders, gastrointestinal disorders, and death; see Analysis 5.6 and Analysis 5.7. There were no statistically significant differences in the number of participants on chlorproguanil-dapsone reporting any adverse event compared with sulfadoxine-pyrimethamine (RR 0.97, 95% CI 0.87 to 1.09; n = 2679). Both trials reported serious adverse events. Sulo 2002 reported severe malaria leading to hospitalization (n = 60) and death (n = 1), with no statistically significant difference between the groups (RR 0.99, 95% CI 0.61 to 1.61, n = 829). Alloueche 2004 defined serious adverse events as serious "Treatment Emergent Signs and Symptoms (TESS)" (see Analysis 5.7), and also reported no statistically significant difference between the two groups (RR 1.00, 95% CI 0.34 to 2.97; n = 1850), although serious red blood cells disorders appeared more common in people treated with chlorproguanil-dapsone. Sulo 2002 reported on adverse events leading to discontinuation of treatment, and that they were more common with chlorproguanildapsone than sulfadoxine-pyrimethamine (RR 4.54, 95% CI 1.74 to 11.82; n = 829). The primary outcome for Alloueche 2004 was safety and accordingly provided more adverse event data than the other trials (see Table 4 ). There were more TESS probably related to the intervention in the chlorproguanil-dapsone group (RR 1.62, 95% CI 1.09 to 2.40; n = 1850). The most commonly reported adverse events were red blood cells disorders. These were also more common on chlorproguanil-dapsone compared with sulfadoxinepyrimethamine (80/1480 on chlorproguanil-dapsone, 7/370 on sulfadoxine-pyrimethamine; RR 2.86, 95% CI 1.33 to 6.13, n = 1850). Clinically significant methaemoglobinaemia (defined as values exceeding 10%) was also seen far more frequently on chlorproguanil-dapsone compared with sulfadoxine-pyrimethamine, but this was only measured in one site (Kenya) and was not statistically significant (RR 15.78, 95% CI 0.97 to 257.15). There was a statistically significant difference in mean methaemoglobin (reported as a percentage of total haemoglobin) on day three in favour of sulfadoxine-pyrimethamine (MD 3.8 g/dL, 95% CI 3.4 to 4.2). There was a tendency for anaemia, haemolysis, and haemolytic anaemia to be more common in participants treated with chlorproguanil-dapsone, but these were not statistically significant. 
D I S C U S S I O N
The trials were of variable methodological quality. Mutabingwa 2001 was carried out with participants who had already failed on sulfadoxine-pyrimethamine, and it cannot be regarded as a first-line comparison between chlorproguanil-dapsone and sulfadoxine-pyrimethamine.
Three trials using the lower dose of chlorproguanil (1.2 mg) examined day 28 parasitaemia and treatment failure (Watkins 1988; Keuter 1990; Amukoye 1997) . The results show that both the one-dose regimen (3 trials) and three-dose regimen (1 trial) were generally less effective than one-dose sulfadoxine-pyrimethamine regimen.
One trial using the current standard dosing regimen (with 2 mg chlorproguanil) compared this with sulfadoxine-pyrimethamine in participants who were selected on the basis of previous failure to sulfadoxine-pyrimethamine (Mutabingwa 2001) . It is therefore difficult to draw any conclusions about comparative effectiveness of these two drugs given that the participants selected are more likely to have infections resistant to sulfadoxine-pyrimethamine.
No information is available at 28 days using the current standard dosing regimen (with 2 mg chlorproguanil) for parasitaemia or treatment failure by day 28. One trial measured this according to the stated methods (Sulo 2002), but did not report results for it; and the most recent trial, Alloueche 2004, stopped follow up at day 14. Some recent evidence suggests day 14 treatment failure may have no predictive value in identifying true failures (Stepniewska 2004) . There is thus currently insufficient evidence to be clear whether chlorproguanil-dapsone is superior or inferior to sulfadoxine-pyrimethamine.
All the trials mentioned adverse events, but only two described the procedure to assess them (Sulo 2002; Alloueche 2004), which creates uncertainty over the completeness of these data. Also, the day of treatment when adverse events occurred were not always reported, and thus it was not possible to report this information in this review. Serious adverse events tended to be commoner with chlorproguanil-dapsone, but overall this was not statistically significant. Red blood cells disorders were more common in participants treated with chlorproguanil-dapsone, and Looareesuwan 2004 comments on aspects of safety in a Lancet editorial.
Although Keuter 1990 included pregnant women, it is still not possible to conclusively determine the effectiveness and safety of chlorproguanil-dapsone in this group because participants were a mixed group, numbers for important outcomes were sometimes too few, and adverse event outcomes were not reported.
A U T H O R S ' C O N C L U S I O N S Implications for practice
No data are available after day 14 for the current standard chlorproguanil-dapsone regimen (three doses, 2 mg chlorproguanil), and therefore there is insufficient evidence to know whether this drug is inferior or superior to current regimens of chloroquine or sulfadoxine-pyrimethamine.
2008: Chlorproguanil-dapsone was withdrawn in 2008 (see the 'What's new' statement), and the review will not be updated.
Implications for research
2008: Chlorproguanil-dapsone was withdrawn in 2008 (see the 'What's new' statement).
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R E F E R E N C E S
References to studies included in this review
Alloueche-Tanzania {published and unpublished data}
C H A R A C T E R I S T I C S O F S T U D I E S Characteristics of included studies [ordered by study ID]
Alloueche 2004
Methods Randomized controlled trial (randomized parallel design). 
Alloueche-Gabon
Methods
Gabon site in Alloueche 2004
Participants -
Interventions -
Outcomes -
Notes -
Alloueche-Kenya
Methods
Kenya site in Alloueche 2004
Alloueche-Kenya (Continued)
Interventions -
Outcomes -
Notes -
Alloueche-Malawi
Methods
Malawi site in Alloueche 2004
Interventions -
Notes -
Alloueche-Nigeria
Methods
Nigeria site in Alloueche 2004
Interventions -
Notes -
Alloueche-Tanzania
Methods
Tanzania site in Alloueche 2004
Interventions -
Notes -
Sulo 2002
Methods Randomized controlled trial (parallel treatment groups) Multicentre trial with one arm in Kilifi, Kenya (Sulo-Kenya) and other arm in Blantyre, Malawi (Sulo-Malawi) Length of follow up: aimed at 1 year when incidence of malaria episodes was recorded and same drug given for each episode Intention-to-treat analysis: used only for treatment failure outcome Participants Enrolled febrile children aged 3 to 71 months: 410 in Kilifi and 500 in Blantyre Inclusion criteria: uncomplicated malaria; well enough for outpatient care; capillary haemoglobin at least 70 g/L; falciparum parasitaemia below 250,000/µL blood Exclusion criteria: children with concurrent infection; allergy to sulfonamides; or treatment within last week with sulfadoxine-pyrimethamine, pyrimethamine-sulfalene, mefloquine, amodiaquine, halofantrine, or quinine; chloroquine treatment at an earlier date was not an exclusion criterion Interventions 1. Chlorproguanil (2 mg/kg) + dapsone (2.5 mg/kg), once daily for 3 days (3-dose regimen) 2. Sulfadoxine (25 mg/kg) + pyrimethamine (1.25 mg/kg), 1 dose followed with placebo for 2 days All participants were given paracetamol Favours chlor-dap Favours SP
